Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report)'s share price gapped down before the market opened on Monday . The stock had previously closed at $12.14, but opened at $11.85. Sionna Therapeutics shares last traded at $12.31, with a volume of 562 shares traded.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on the company. Guggenheim initiated coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a "buy" rating and a $45.00 target price for the company. TD Cowen initiated coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating for the company. Finally, Stifel Nicolaus began coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating and a $32.00 price objective on the stock.
Check Out Our Latest Analysis on SION
Sionna Therapeutics Stock Performance
The firm has a 50 day moving average price of $12.99.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($3.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.68) by ($0.70).
About Sionna Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
